miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer

详细信息    查看全文

• 作者：Tianjun Chen ^{tjchen223@163.com} ; Hui Ren ^{hren223@163.com} ; Asmitanand Thakur ^{thakur223@163.com} ; Tian Yang ^{tyang223@163.com} ; Yang Li ^{yangli223a@163.com} ; Shuo Zhang ^{sqzhang585@163.com} ; Ting Wang ^{yczhang546@163.com} ; Mingwei Chen ; ^{mwchen223@163.com}
• 关键词：miR-382 ; SETD8 ; Non-small cell lung cancer ; Proliferation ; Migration ; Invasion
• 刊名：Biomedicine & Pharmacotherapy
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：86
• 期：Complete
• 页码：248-253
• 全文大小：1839 K
• 卷排序：86

文摘

Previous studies showed that miR-382 plays important roles in several types of cancers. Nevertheless, its expression and function in non-small cell lung cancer (NSCLC) remains largely unknown. In this study, we found that miR-382 expression was evidently downregulated in NSCLC tissue and cell lines in comparison with the adjacent normal tissues and human bronchial epithelial cell line (16HBE). Moreover, the expression levels of miR-382 were significantly associated with last-stage and tumor metastasis in NSCLC patients. In addition, exogenous miR-382 evidently inhibited NSCLC cell proliferation, migration and invasion in vitro. We also revealed SETD8 as a direct target of miR-382 in NSCLC, and restored SETD8 partially reversed the negative effects miR-382 on NSCLC cells. In total, our study demonstrated that miR-382 dysregulated in NSCLC and involved in NSCLC tumorigenesis and metastasis by suppressing SETD8 expression, which may help to identify effective therapies for NSCLC treatment.